Tonix Pharmaceuticals has unveiled groundbreaking data on their new single-dose vaccine for Mpox and Smallpox, showcasing an impressive 100,000-fold improvement in safety. This remarkable achievement stems from recent trials demonstrating the vaccine’s unprecedented protective efficacy and its ability to provide robust immunity with just one dose. The findings, presented at a recent scientific conference, highlight the immense potential of this vaccine to revolutionize existing practices in combating these infections. Experts are optimistic that this advancement could significantly enhance global health security, especially in regions prone to these diseases. Tonix Pharmaceuticals’ commitment to innovation in the field of vaccines is evident, as this development marks a significant milestone in public health safety. As the demand for effective and safe vaccines continues to grow, this new data positions Tonix at the forefront of infectious disease prevention. The dissemination of these findings could pave the way for rapid deployment in affected regions.
Stock TitanNew data shows concerning air pollution levels in New Zealand: Only a quarter of sites meet safety guidelines
June 5, 2026
Recent data reveals that only 25% of monitoring sites across New Zealand meet the safety guidelines for air pollution concerning the most harmful airborne particles.